GeoVax Labs, Inc. (GOVX) News & Overview - Discounting Cash Flows
GeoVax Labs, Inc.
GOVX (NASDAQ)
Open 0.5672
Previous Close 0.8657
Volume 15.85 Mil.
Average Volume 1.03 Mil.
Day's Range 0.4319 โ€“ 0.5811
52 Week Range 0.43-11.18
Market Cap 7.72 Mil.
Moving Average (50) 0.98652
Moving Average (200) 1.75776
Earnings per Share (EPS) -2.8
Price/Earnings (PE) -0.17
Shares Outstanding 15.92 Mil.
Earnings Date Aug 04, 2025
Beta 3.442
Last Dividend 0

GOVX Latest News

GOVX Business Model

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

About GeoVax Labs
Industry Biotechnology
Sector Healthcare
Number of Employees 17
Website & Executive
Website https://www.geovax.com
CEO (Chief Executive Officer) David Alan Dodd
IPO date 2020-09-25
Contact
Country US
Address 1900 Lake Park Drive
City Smyrna
State GA
Phone 678 384 7220
Zip Code 30080
Other Identifiers
CIK 0000832489
ISIN US3736786068
CUSIP 373678507
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us